MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says ...

Basophils trigger a cytokine cascade that improves antitumor immunity in mice, offering potential targets for cancer ...

Nutritionists share the best time to take vitamin B supplements, if it needs to be taken with food, its benefits and risks, ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...